ProQR Therapeutics NV
NASDAQ:PRQR

Watchlist Manager
ProQR Therapeutics NV Logo
ProQR Therapeutics NV
NASDAQ:PRQR
Watchlist
Price: 2.16 USD -2.7%
Market Cap: 227.3m USD

EV/EBIT
Enterprise Value to EBIT

-2.2
Current
-2
Median
6.4
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-2.2
=
Enterprise Value
106.4m USD
/
EBIT
-41.9m EUR
EBIT Growth EV/EBIT to Growth
NL
ProQR Therapeutics NV
NASDAQ:PRQR
Average EV/EBIT: 24.1
Negative Multiple: -2.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 826.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
19%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.1
13%
0.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -555.1 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.2
17%
1.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
12%
1.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -310.9 N/A N/A
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
NL
argenx SE
XBRU:ARGX
61.5
N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-2.1
2-Years Forward
EV/EBIT
-1.8
3-Years Forward
EV/EBIT
-1.3